Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158506 · ClinicalTrials.gov registry record · Phase 1
Human Mass Balance Study of HMS5552 in Healthy Subjects
A Phase 1 study, sponsored by Hua Medicine Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03158506: Completed Phase 1 study, sponsored by Hua Medicine Limited.
NCT03158506 is a Phase 1 study that has completed, run by Hua Medicine Limited. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03158506, a Phase 1 study, has completed, sponsored by Hua Medicine Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is an open-label, single center, 1-period study in healthy adult male subjects to assess absorption, metabolism, and excretion of HMS5552 after a single oral administration of 50 mg (90 μCi) of \[14C\]-HMS5552.
Primary Outcome
Peak plasma concentration (Cmax)
Interventions
- DRUG HMS5552
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2017-04-06 |
| Phase | Phase 1 |
What the finished NCT03158506 record still lists
NCT03158506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which HMS5552 is the first listed.
NCT03158506 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03158506 about?
NCT03158506 is a clinical study titled "Human Mass Balance Study of HMS5552 in Healthy Subjects". This is an open-label, single center, 1-period study in healthy adult male subjects to assess absorption, metabolism, and excretion of HMS5552 after a single oral administration of 50 mg (90 μCi) of \[14C\]-HMS5552.
What is the current status of trial NCT03158506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-03-29. Estimated completion is 2017-04-06.
What interventions are being tested in trial NCT03158506?
The interventions under investigation include: HMS5552 (DRUG).
Who is sponsoring clinical trial NCT03158506?
This trial is sponsored by Hua Medicine Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03158506's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI